Title:
PHARMACEUTICAL COMBINATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/274275
Kind Code:
A1
Abstract:
a pharmaceutical combination and a use thereof. The pharmaceutical combination comprises a PD-1 inhibitor and/or a PD-L1 immune checkpoint inhibitor, as well as a Toll-like receptor agonist. The present pharmaceutical combination has a better medicinal effect than only using an immune checkpoint inhibitor or only using a Toll-like receptor agonist, treatment using a two-pronged approach of activation of an innate immune pathway and prevention of immune escape is implemented, and the present invention has clinical application prospects as being highly effective and having low toxicity.
Inventors:
WANG CHENGUANG (CN)
ZHANG XIAOJIAO (CN)
DANG XIAOMENG (CN)
ZHANG JIN (CN)
FU YUTING (CN)
WANG YIHAN (CN)
WANG CHAO (CN)
ZHANG XIAOJIAO (CN)
DANG XIAOMENG (CN)
ZHANG JIN (CN)
FU YUTING (CN)
WANG YIHAN (CN)
WANG CHAO (CN)
Application Number:
PCT/CN2022/102169
Publication Date:
January 05, 2023
Filing Date:
June 29, 2022
Export Citation:
Assignee:
TIANJIN LIPOGEN TECH CO LTD (CN)
International Classes:
A61K39/00; C07K16/28
Domestic Patent References:
| WO2019171253A1 | 2019-09-12 |
Foreign References:
| CN108025051A | 2018-05-11 | |||
| CN106008714A | 2016-10-12 | |||
| CN105968200A | 2016-09-28 | |||
| CN112679615A | 2021-04-20 | |||
| CN107207593A | 2017-09-26 |
Other References:
SATO-KANEKO, F. ET AL.: "Combination Immunotherapy with TLR Agonists and Checkpoint Inhibitors Suppresses Head and Neck Cancer", JCI INSIGHT, vol. 2, no. 18, 21 September 2017 (2017-09-21), XP055536220, DOI: 10.1172/jci.insight.93397
Attorney, Agent or Firm:
SHANGHAI DIANSHI PARTNERS, P.C. (CN)
Download PDF:
Previous Patent: FAULT PROMPT METHOD FOR REFRIGERATOR
Next Patent: ANTI-GFRAL ANTIBODY AND APPLICATION THEREOF
Next Patent: ANTI-GFRAL ANTIBODY AND APPLICATION THEREOF